Should I buy Zoetis (ZTS) stock or is it too late?

Zoetis · Health Care · price $75

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $99 (+32 %), call made on July 23, 2026, maturing on July 23, 2027 (36 d ago).

The 8 reliable analysts $89.50+19 %

The 2 other firms $103+37 %

How to read it: the 8 reliable firms are not filtered by optimism — 8 aim above the price, 0 below, hence their $89.50 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Zoetis

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
JP Morgan	71 %	+14.6 %	7	$115 +53%
Argus Research	60 %	+7.3 %	5	$190 +153%
B of A Securities	70 %	+7.2 %	10	$140 +87%
Stifel	43 %	-0.3 %	21	$80 +7%
Barclays	46 %	-0.5 %	13	$85 +13%
Morgan Stanley	43 %	-9.8 %	7	$99 +32%
Piper Sandler	8 %	-17.6 %	12	$80 +7%
Jefferies	79 %	+19.8 %	14	—

In short — Should you invest in Zoetis? Is it too late, still worth it? Analysts are split (50% buy, median target $95, i.e. +26%), and the most reliable on ZTS targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $95, i.e. +26% from the current price ($75).
The most reliable firm on ZTS, JP Morgan (71% hit rate, 7 scored calls), targets $115 (call made on August 7, 2026, maturing on August 7, 2027) (+53%) in its most recent call, and $200 (call made on November 5, 2025, maturing on November 5, 2026) (+167%) in the one coming due soonest.
Pays a dividend (2.8% yield), raised for 12 years — regular income on top of potential upside.
Reasonable valuation (P/E ~13) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 12 ratings, 6 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on ZTS

Median target $95 (+26%) · 12 ratings · Buy consensus

Strong Buy00%

Buy650%

Hold650%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Zoetis now?

We won't decide for you. The facts: 50% of analysts rate it a buy, median target $95 (+26%), and JP Morgan (most reliable on ZTS, 71%) targets $115. Weigh that against valuation (P/E ~13). This is not personalized advice.

Is it too late to invest in Zoetis?

Not according to analysts: the median target ($95) is still +26% above the current price ($75) (most reliable on ZTS: JP Morgan, 71%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Zoetis still worth investing in?

It depends on the gap between the price ($75) and its estimated value: analysts target $95 on median (+26%), with 50% buys (most reliable on ZTS: JP Morgan, 71%). Cross-check with their real reliability on ZTS and the cautions above. Information, not advice.

What's the main risk in buying ZTS?

The consensus is not unanimous: of 12 ratings, 6 are neutral.

→ Go deeper: the full Zoetis profile (consensus, analyst reliability, price target, performance).